Therapy for hepatitis C virus infection increases survival of patients with pretreatment anemia.

[1]  M. Kurosaki,et al.  Pretreatment prediction of anemia progression by pegylated interferon alpha-2b plus ribavirin combination therapy in chronic hepatitis C infection: decision-tree analysis , 2011, Journal of Gastroenterology.

[2]  P. Belperio,et al.  A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[3]  G. Dore,et al.  Virological response is associated with decline in hemoglobin concentration during pegylated interferon and ribavirin therapy in hepatitis C virus genotype 1 , 2011, Hepatology.

[4]  Stefan Zeuzem,et al.  Boceprevir for previously treated chronic HCV genotype 1 infection. , 2011, The New England journal of medicine.

[5]  D. Samuel,et al.  Low-dose peginterferon alfa-2a is safe and produces a sustained virologic response in patients with chronic hepatitis C and end-stage renal disease. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[6]  L. Fried,et al.  HCV infection and the incidence of CKD. , 2011, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[7]  H. Sørensen,et al.  Increased mortality among persons infected with hepatitis C virus. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[8]  William M. Lee,et al.  Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate. , 2010, Gastroenterology.

[9]  H. El‐Serag,et al.  Prevalence and challenges of liver diseases in patients with chronic hepatitis C virus infection. , 2010, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[10]  E. Schiff,et al.  Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial , 2010, The Lancet.

[11]  S. Saab,et al.  Timing of hepatitis C antiviral therapy in patients with advanced liver disease: A decision analysis model , 2010, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[12]  A. Justice,et al.  Hepatitis C treatment completion rates in routine clinical care , 2010, Liver international : official journal of the International Association for the Study of the Liver.

[13]  D. Bulchandani,et al.  Predictors of hematological abnormalities in patients with chronic hepatitis C treated with interferon and ribavirin , 2010, Annals of Hematology.

[14]  A. D. de Craen,et al.  Effect of anemia and comorbidity on functional status and mortality in old age: results from the Leiden 85-plus Study , 2009, Canadian Medical Association Journal.

[15]  A. Butt,et al.  Effect of hepatitis C virus and its treatment on survival , 2009, Hepatology.

[16]  G. Everson,et al.  Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. , 2009, The New England journal of medicine.

[17]  E. McLean,et al.  Worldwide prevalence of anaemia, WHO Vitamin and Mineral Nutrition Information System, 1993–2005 , 2009, Public Health Nutrition.

[18]  J. Tsevat,et al.  Rates of HCV Treatment Eligibility Among HCV-Monoinfected and HCV/HIV-Coinfected Patients in Tertiary Care Referral Centers , 2009 .

[19]  G. Apolone,et al.  Association of mild anemia with hospitalization and mortality in the elderly: the Health and Anemia population-based study , 2009, Haematologica.

[20]  S. Crystal,et al.  HIV infection and the risk of diabetes mellitus , 2008, AIDS.

[21]  H. Hillege,et al.  Anemia and mortality in heart failure patients a systematic review and meta-analysis. , 2008, Journal of the American College of Cardiology.

[22]  C. Polanczyk,et al.  Association of anemia with clinical outcomes in stable coronary artery disease , 2008, Coronary artery disease.

[23]  Peter J. Hurley,et al.  Development and Verification of TAPM , 2008 .

[24]  C. Kwoh,et al.  Co‐morbid medical and psychiatric illness and substance abuse in HCV‐infected and uninfected veterans , 2007 .

[25]  C. Kwoh,et al.  Rate and predictors of treatment prescription for hepatitis C , 2006, Gut.

[26]  J. Schmier,et al.  Anemia, costs and mortality in Chronic Obstructive Pulmonary Disease , 2006, Cost effectiveness and resource allocation : C/E.

[27]  Melissa Skanderson,et al.  Development and Verification of a “Virtual” Cohort Using the National VA Health Information System , 2006, Medical care.

[28]  M. Alter,et al.  The Prevalence of Hepatitis C Virus Infection in the United States, 1999 through 2002 , 2006, Annals of Internal Medicine.

[29]  H. Nomura,et al.  Factors contributing to ribavirin‐induced anemia , 2004, Journal of gastroenterology and hepatology.

[30]  S S Lee,et al.  Cost-Effectiveness of Combination Peginterferon α-2a and Ribavirin Compared With Interferon α-2b and Ribavirin in Patients With Chronic Hepatitis C , 2004, American Journal of Gastroenterology.

[31]  Yoshiyuki Suzuki,et al.  Factors contributing to ribavirin dose reduction due to anemia during interferon alfa2b and ribavirin combination therapy for chronic hepatitis C , 2004, Journal of Gastroenterology.

[32]  M. Fried.  Side effects of therapy of hepatitis C and their management , 2002 .

[33]  H. El‐Serag.  Hepatocellular carcinoma and hepatitis C in the United States , 2002, Hepatology.

[34]  J. M. Calvo Romero,et al.  Gastric adenocarcinoma and kidney transplantation , 1998 .

[35]  P. Sullivan,et al.  Epidemiology of Anemia in Human Immunodeficiency Virus (HIV)-Infected Persons: Results From the Multistate Adult and Adolescent Spectrum of HIV Disease Surveillance Project , 1998 .